Christophe Weber | President & CEO Andy Plump | President, R&D Costa Saroukos | Chief Financial Officer Julie Kim | US Business Unit PLAY LIST from the beginning Takeda IR Call @ Takeda to acquire late-stage, potential best-in-class, oral allosteric TYK2 inhibitor NDI-034858 from Nimbus Therapeutics NDI-034858, a selective allosteric tyrosine kinase 2 (TYK2) inhibitor Potential best-in-class efficacy & safety in multiple immune-mediated diseases Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 @ Back Next